Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 P524 | DOI: 10.1530/endoabs.99.P524

1Ramón y Cajal Hospital, Endocrinology & Nutrition, Madrid, Spain; 2Hospital Universitario de Toledo, Endocrinology & Nutrition, Toledo, Spain; 3Hospital Universitario de Coruña, Coruña, Spain; 4Hospital Universitario Central de Asturias, Asturias, Spain; 5Hospital Universitario Virgen del Rocío, Sevilla, Spain; 6Hospital Gregorio Marañón, Madrid, Spain; 7Hospital Santiago de Compostela, Spain; 8Hospital Universitari de Bellvitge., Spain; 9Hospital Universitario de Castellón, Spain; 10Hospital Clinic de Barcelona, Spain; 11Hospital Ribera, Spain; 12Hospital Virgen de las Nieves, Spain; 13Hospital Universitario La Fe, Spain; 14Hospital Universitario San Cecilio., Spain; 15Hospital Universitario la Princesa, Spain; 16Hospital Universitario Vall d’Hebrón, Spain; 17Hospital Germans Trias i Pujol, Spain


Aim: To evaluate the efficacy of second-line therapies in patients with acromegaly caused by a GH and PRL cosecreting pituitary neuroendocrine tumor (GH&PRL-Pit-NET) and those caused by a GH-Pit-NET.

Methods: A multicenter retrospective clinical practice study of 679 patients with acromegaly in follow-up in 33 tertiary hospitals (ACRO-SPAIN study). For this analysis, only patients on treatment with pasireotide or pegvisomant in monotherapy or in combination with other drugs were included (n=150; 22.1%). Patients were classified in two groups: GH-Pit-NET if PRL levels were normal (n=122) and GH&PRL-Pit-NET when evidence of hyperprolactinemia and immunohistochemistry (IHC) for GH and PRL was positive or if PRL levels were >100ng/dl regardless of the PRL IHC (n=28).

Results: A total of 150 patients with acromegaly accomplish the inclusion criteria. A total of 124 patients were treated with pegvisomant and 49 with pasireotide at any time (Table 1). The median time of treatment was of 30.8 months (IQR=15.9-58.2) with pasireotide and 100 months (IQR=34.4-138.5) with pegvisomant. No differences in IGF1 control with pasireotide neither with pegvisomant were observed between GH&PRL-Pit-NETs and GH-Pit-NETs (Table 1). All GH&PRL-Pit-NET cases treated with pasireotide (n=6) and 82.6% (n=19/23) of the cases treated with pegvisomant normalized PRL levels. No differences in the rate of IGF1 control between pegvisomant (in monotherapy or combined with dopamine agonists) vs pasireotide (in monotherapy or combined with dopamine agonists) were detected in patients with GH&PRL-Pit-NET (84.9% vs 66.7%, P=0.178). Neither in the rate of PRL control (80% vs 100%, P=0.234).

Table 1. Differences in the acromegaly presentation and in the response to second-line medical therapies between GH-Pit-NETs and GH&PRL-Pit-NETs
GH-Pit-NET (n=122)GH&PRL-Pit-NET (n=28)P value
CLINICO-RADIOLOGICAL DATA AT ACROMEGALy DIAGNOSIS
Age (years)46.2±16.0338.0±13.770.017
Knosp>2 (n=118)51.7% (n=47/91)74.1% (n=20/27)0.039
EFFICACy OF SECOND-LINE MEDICAL THERAPIES (IGF normalization)
Pasireotide monotherapy or combined with DA (n=43)66.7% (n=24/36)71.4% (n=5/7)0.806
Pasireotide monotherapy (n=24)69.6% (n=16/23)100% (n=1)0.512
Pasireotide+DA61.5% (n=8/13)66.7% (n=4/6)0.829
Pegvisomant monotherapy or combined with DA/f-SRL (n=118)84.4% (n=81/96)77.3% (n=17/22)0.423
Pegvisomant monotherapy (n=45)85.7% (n=30/35)80% (n=8/10)0.660
Pegvisomant+f-SRL (n=43)79.5% (n=31/39)100% (n=4)0.315
Pegvisomant+DA (n=20)86.7% (n=13/15)60% (n=3/5)0.197
Pegvisomant+pasireotide (n=6)40% (n=2/5)100% (n=1)0.273
DA=dopamine agonists; f-SRL= first generation somatostatin receptor ligands

Conclusion: GH&PRL-Pit-NETs are invasive tumors and present at a younger age than GH-Pit-NETs. However, no differences in the rate of IGF-1 biochemical control with second line therapies were observed between both groups.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.